These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38013580)

  • 1. The Dilemma Of Pharmaceutical Companies In Pakistan: Navigating Price Regulations During A Time Of High Inflation.
    Mansoor N; Warsi A
    J Pak Med Assoc; 2023 Nov; 73(11):2327-2328. PubMed ID: 38013580
    [No Abstract]   [Full Text] [Related]  

  • 2. The healthcare field as a marketplace: general practitioners, pharmaceutical companies, and profit-led prescribing in Pakistan.
    Noor MN; Liverani M; Bryant J; Rahman-Shepherd A; Sharif S; Aftab W; Shakoor S; Khan M; Hasan R
    Health Sociol Rev; 2023 Jul; 32(2):198-212. PubMed ID: 36322797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions of and barriers to ethical promotion of pharmaceuticals in Pakistan: perspectives of medical representatives and doctors.
    Gul R; Saeed H; Saleem Z; Rasool F; Hashmi FK; Islam M; Imran I; Raza SA; Danish Z
    BMC Med Ethics; 2021 Jan; 22(1):2. PubMed ID: 33397339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
    Quraeshi ZA; Luqmani M; Malhotra N
    J Health Care Mark; 1983; 3(4):27-37. PubMed ID: 10264767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflict Of Interests Driven By Pharmaceutical Incentivisation: Risks To The Medical Fraternity In Pakistan.
    Noor MN; Shepherd AR; Siddiqui AR
    J Pak Med Assoc; 2023 Nov; 73(11):2150-2151. PubMed ID: 38013517
    [No Abstract]   [Full Text] [Related]  

  • 6. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
    Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R
    J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicines shortages in Pakistan: a qualitative study to explore current situation, reasons and possible solutions to overcome the barriers.
    Atif M; Malik I; Mushtaq I; Asghar S
    BMJ Open; 2019 Sep; 9(9):e027028. PubMed ID: 31488466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses from pharmaceutical companies to doctors' requests for more drug information in Pakistan: postal survey.
    Hafeez A; Mirza Z
    BMJ; 1999 Aug; 319(7209):547. PubMed ID: 10463894
    [No Abstract]   [Full Text] [Related]  

  • 10. Socioecological factors linked with pharmaceutical incentive-driven prescribing in Pakistan.
    Noor MN; Rahman-Shepherd A; Siddiqui AR; Aftab W; Shakoor S; Hasan R; Khan M
    BMJ Glob Health; 2023 Feb; 6(Suppl 3):. PubMed ID: 36731921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health and the legal regulation of the pharmaceutical industry in Algeria.
    Alsamara T; Farouk G; Adel A
    Pan Afr Med J; 2022; 41():86. PubMed ID: 35432697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
    Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
    Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
    Golec J; Vernon JA
    Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes of medical students towards incentives offered by pharmaceutical companies -- perspective from a developing nation -- a cross-sectional study.
    Siddiqui UT; Shakoor A; Kiani S; Ali F; Sharif M; Kumar A; Raza Q; Khan N; Alamzaib SM; Farid-ul-Husnain S
    BMC Med Ethics; 2014 May; 15():36. PubMed ID: 24885167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
    Tauqeer F; Myhr K; Gopinathan U
    Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The pharmaceutical industry in France: the turning point of 1915].
    Bonnemain B
    Rev Hist Pharm (Paris); 2015 Dec; 63(388):399-422. PubMed ID: 26827550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marketing Antipsychotics to Correctional Facilities: A Review of Pharmaceutical Industry Documents.
    Apollonio DE
    J Correct Health Care; 2022 Oct; 28(5):325-328. PubMed ID: 36190495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.